S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
NYSE:NVTA

Invitae (NVTA) Stock Price, News & Analysis

$0.01
0.00 (-10.00%)
(As of 03/27/2024 ET)
Today's Range
$0.0111
$0.0160
50-Day Range
$0.01
$0.45
52-Week Range
$0.02
$0.02
Volume
3.31 million shs
Average Volume
23.72 million shs
Market Capitalization
$3.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.00

Invitae MarketRank™ Stock Analysis

Analyst Rating
Strong Sell
1.00 Rating Score
Upside/​Downside
8,447.0% Upside
$1.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.13
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.05) to ($0.89) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.11 out of 5 stars

NVTA stock logo

About Invitae Stock (NYSE:NVTA)

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

NVTA Stock Price History

NVTA Stock News Headlines

The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
NVTA.PK
NVTA.N
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
NVTA Jun 2024 0.500 put
NVTA Jan 2026 1.500 call
NVTA Mar 2024 0.500 put
Invitae Corp.
Why Is Invitae (NVTA) Stock Down 75% Today?
See More Headlines
Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2023
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Fax
N/A
Employees
1,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.00
High Stock Price Target
$1.50
Low Stock Price Target
$0.50
Potential Upside/Downside
+7,592.3%
Consensus Rating
Strong Sell
Rating Score (0-4)
1.00
Research Coverage
3 Analysts

Profitability

Net Income
$-3,106,290,000.00
Net Margins
-299.14%
Pretax Margin
-301.93%

Debt

Sales & Book Value

Annual Sales
$481.58 million
Book Value
$0.42 per share

Miscellaneous

Free Float
284,373,000
Market Cap
$3.47 million
Optionable
Optionable
Beta
1.59
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives


NVTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Invitae stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last year. There are currently 3 sell ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "strong sell" NVTA shares.
View NVTA analyst ratings
or view top-rated stocks.

What is Invitae's stock price target for 2024?

3 Wall Street analysts have issued 12-month target prices for Invitae's shares. Their NVTA share price targets range from $0.50 to $1.50. On average, they predict the company's stock price to reach $1.00 in the next year. This suggests a possible upside of 8,447.0% from the stock's current price.
View analysts price targets for NVTA
or view top-rated stocks among Wall Street analysts.

How have NVTA shares performed in 2024?

Invitae's stock was trading at $0.6268 at the start of the year. Since then, NVTA stock has decreased by 98.1% and is now trading at $0.0117.
View the best growth stocks for 2024 here
.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) announced its quarterly earnings data on Tuesday, May, 9th. The medical research company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.04. The medical research company had revenue of $117.36 million for the quarter, compared to analyst estimates of $116.57 million. Invitae had a negative net margin of 299.14% and a negative trailing twelve-month return on equity of 6,100.71%. The firm's revenue was down 5.1% on a year-over-year basis. During the same period last year, the company earned ($0.78) EPS.

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

Invitae (NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

Who are Invitae's major shareholders?

Invitae's stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (11.36%), Vanguard Group Inc. (5.12%), Vanguard Group Inc. (5.49%), UBS Group AG (0.41%), Goldman Sachs Group Inc. (0.37%) and State of Michigan Retirement System (0.34%). Insiders that own company stock include Artur Bergman, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen.
View institutional ownership trends
.

How do I buy shares of Invitae?

Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NVTA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners